Lutetium-177 Prostate-Specific Membrane Antigen Therapy: A Practical Review

Angela Y. Jia, Rojano Kashani, Nicholas G. Zaorsky, Brian C. Baumann, Jeff Michalski, Jacqueline E. Zoberi, Ana P. Kiess, Daniel E. Spratt

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Prostate-specific membrane antigen is a transmembrane protein found predominately on prostate epithelium and is expressed at high levels in prostate cancer. In this review, we discuss the background, clinical data, patient selection, side effects, and necessary resources to deliver lutetium-177 prostate-specific membrane antigen in the research setting, or as standard of care if approved by the United States Food and Drug Administration. Targeted radionuclide therapeutics require understanding of fundamental principles of radiobiology and physics, and radiation oncologists and medical physicists are well-suited to play an integral role in their delivery and treatment response monitoring as key components of a multidisciplinary care team.

Original languageEnglish
Pages (from-to)294-299
Number of pages6
JournalPractical Radiation Oncology
Issue number4
StatePublished - Jul 1 2022


Dive into the research topics of 'Lutetium-177 Prostate-Specific Membrane Antigen Therapy: A Practical Review'. Together they form a unique fingerprint.

Cite this